| In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 LT Vassilev, BT Vu, B Graves, D Carvajal, F Podlaski, Z Filipovic, N Kong, ... Science 303 (5659), 844-848, 2004 | 5552 | 2004 |
| Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell … E Mössner, P Brünker, S Moser, U Püntener, C Schmidt, S Herter, R Grau, ... Blood, The Journal of the American Society of Hematology 115 (22), 4393-4402, 2010 | 1088 | 2010 |
| A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade DS Thommen, VH Koelzer, P Herzig, A Roller, M Trefny, S Dimeloe, ... Nature medicine 24 (7), 994-1004, 2018 | 980 | 2018 |
| Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies W Schaefer, JT Regula, M Bähner, J Schanzer, R Croasdale, H Dürr, ... Proceedings of the National academy of Sciences 108 (27), 11187-11192, 2011 | 553 | 2011 |
| Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling M Felcht, R Luck, A Schering, P Seidel, K Srivastava, J Hu, A Bartol, ... The Journal of clinical investigation 122 (6), 1991-2005, 2012 | 518 | 2012 |
| Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors DS Thommen, J Schreiner, P Müller, P Herzig, A Roller, A Belousov, ... Cancer immunology research 3 (12), 1344-1355, 2015 | 398 | 2015 |
| Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models S Herter, F Herting, O Mundigl, I Waldhauer, T Weinzierl, T Fauti, G Muth, ... Molecular cancer therapeutics 12 (10), 2031-2042, 2013 | 384 | 2013 |
| Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties C Klein, A Lammens, W Schäfer, G Georges, M Schwaiger, E Mössner, ... MAbs 5 (1), 22-33, 2013 | 381 | 2013 |
| Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53 R Stoll, C Renner, S Hansen, S Palme, C Klein, A Belling, W Zeslawski, ... Biochemistry 40 (2), 336-344, 2001 | 381 | 2001 |
| A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors M Bacac, T Fauti, J Sam, S Colombetti, T Weinzierl, D Ouaret, W Bodmer, ... Clinical Cancer Research 22 (13), 3286-3297, 2016 | 361 | 2016 |
| Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions T Schlothauer, S Herter, CF Koller, S Grau-Richards, V Steinhart, C Spick, ... Protein Engineering, Design and Selection 29 (10), 457-466, 2016 | 334 | 2016 |
| Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy M Mayoux, A Roller, V Pulko, S Sammicheli, S Chen, E Sum, C Jost, ... Science translational medicine 12 (534), eaav7431, 2020 | 327 | 2020 |
| Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment A Seckinger, JA Delgado, S Moser, L Moreno, B Neuber, A Grab, S Lipp, ... Cancer cell 31 (3), 396-410, 2017 | 314 | 2017 |
| WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization Y Tomita, N Marchenko, S Erster, A Nemajerova, A Dehner, C Klein, ... Journal of Biological Chemistry 281 (13), 8600-8606, 2006 | 305 | 2006 |
| Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies G Niederfellner, A Lammens, O Mundigl, GJ Georges, W Schaefer, ... Blood, The Journal of the American Society of Hematology 118 (2), 358-367, 2011 | 299 | 2011 |
| Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab J Golay, F Da Roit, L Bologna, C Ferrara, JH Leusen, A Rambaldi, C Klein, ... Blood, The Journal of the American Society of Hematology 122 (20), 3482-3491, 2013 | 287 | 2013 |
| Targeting key angiogenic pathways with a bispecific Cross MA b optimized for neovascular eye diseases JT Regula, P Lundh von Leithner, R Foxton, VA Barathi, CMG Cheung, ... EMBO molecular medicine 8 (11), 1265-1288, 2016 | 285 | 2016 |
| The N-terminal domain of p53 is natively unfolded R Dawson, L Müller, A Dehner, C Klein, H Kessler, J Buchner Journal of molecular biology 332 (5), 1131-1141, 2003 | 281 | 2003 |
| Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies C Klein, C Sustmann, M Thomas, K Stubenrauch, R Croasdale, ... MAbs 4 (6), 653-663, 2012 | 278 | 2012 |
| Targeting the p53–MDM2 interaction to treat cancer C Klein, LT Vassilev British journal of cancer 91 (8), 1415-1419, 2004 | 266 | 2004 |
Marina BacacRoche在 roche.com 的电子邮件经过验证
